PT  - JOURNAL ARTICLE
AU  - Green, Daniel A.
AU  - Zucker, Jason
AU  - Westblade, Lars F.
AU  - Whittier, Susan
AU  - Rennert, Hanna
AU  - Velu, Priya
AU  - Craney, Arryn
AU  - Cushing, Melissa
AU  - Liu, Dakai
AU  - Sobieszczyk, Magdalena
AU  - Boehme, Amelia K.
AU  - Sepulveda, Jorge L.
TI  - Clinical Performance of SARS-CoV-2 Molecular Testing
AID  - 10.1101/2020.05.06.20093575
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.06.20093575
4099  - http://medrxiv.org/content/early/2020/05/08/2020.05.06.20093575.short
4100  - http://medrxiv.org/content/early/2020/05/08/2020.05.06.20093575.full
AB  - Molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the gold standard for diagnosis of coronavirus disease 2019 (COVID-19), but the test clinical performance is poorly understood. From 3/10/2020-5/1/2020 NewYork-Presbyterian laboratories performed 27,377 SARS-CoV-2 molecular assays from 22,338 patients. Repeat testing was performed in 3,432 patients, of which 2,413 had negative and 1,019 had positive first day results. Repeat-tested patients were more likely to be older, male, African-American or Hispanic, and to have severe disease. Among the patients with initially negative results, 18.6% became positive upon repeat-testing. Only 58.1% of any-time positive patients had a result of “detected” on the first test. The clinical sensitivity of COVID-19 molecular assays is estimated between 66.2 % and 95.6%, depending on the unknown number of false negative results in single-tested patients. Conversion to a negative result is unlikely to occur before 15 to 20 days after initial testing or 20-30 days after the onset of symptoms, with 50% conversion occurring at 28 days after initial testing. Forty-nine initially-positive patients converted to negative and then back to positive in subsequent days. Conversion from first day negative to positive results increased linearly with each day of testing, reaching 25% probability in 20 days. In summary, our study provides estimates of the clinical performance of SARS-CoV-2 molecular assays and suggests time frames for appropriate repeat testing, namely 15 to 20 days after a positive test and the same or next 2 days after a negative test in a patient with high suspicion for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anonymized data stripped of personal health identifiers sufficient for reproducing the results in this manuscript will be shared upon request and review by NYP, Cornell and Columbia Universities.